相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Barth syndrome and the many fascinating aspects of cardiolipin
Frederic M. Vaz et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2022)
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States
Sepehr Farahbakhshian et al.
JOURNAL OF MEDICAL ECONOMICS (2022)
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
Pramod K. Mistry et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Real-world effectiveness of eliglustat in treatment-naive and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
Pramod K. Mistry et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
Elena Lukina et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
Luba Nalysnyk et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe
Nadia Belmatoug et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
Timothy M. Cox et al.
BLOOD (2017)
Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States
Manisha Balwani et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment
Elena Lukina et al.
BLOOD CELLS MOLECULES AND DISEASES (2014)